Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSD NASDAQ:CYCN NASDAQ:EPIX NASDAQ:RDHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.41$1.19$0.37▼$14.09$2.15M2.04220,545 shsN/ACYCNCyclerion Therapeutics$3.27+1.6%$3.11$1.03▼$8.48$13.94M1.7829,311 shs14,015 shsEPIXESSA Pharma$0.20$0.20$0.18▼$1.94$9.52M1.573.75 million shsN/ARDHLRedhill Biopharma$0.93+10.2%$0.94$0.71▼$3.31$4.36M4.98494,621 shs126,371 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical0.00%0.00%0.00%0.00%-96.67%CYCNCyclerion Therapeutics+1.55%+2.83%+2.83%+101.85%+13.54%EPIXESSA Pharma0.00%0.00%0.00%0.00%-88.30%RDHLRedhill Biopharma+10.24%+17.07%-5.50%+4.06%-51.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.41$1.19$0.37▼$14.09$2.15M2.04220,545 shsN/ACYCNCyclerion Therapeutics$3.27+1.6%$3.11$1.03▼$8.48$13.94M1.7829,311 shs14,015 shsEPIXESSA Pharma$0.20$0.20$0.18▼$1.94$9.52M1.573.75 million shsN/ARDHLRedhill Biopharma$0.93+10.2%$0.94$0.71▼$3.31$4.36M4.98494,621 shs126,371 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical0.00%0.00%0.00%0.00%-96.67%CYCNCyclerion Therapeutics+1.55%+2.83%+2.83%+101.85%+13.54%EPIXESSA Pharma0.00%0.00%0.00%0.00%-88.30%RDHLRedhill Biopharma+10.24%+17.07%-5.50%+4.06%-51.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 1.83Reduce$50.0012,095.12% UpsideCYCNCyclerion Therapeutics 1.00SellN/AN/AEPIXESSA Pharma 1.00SellN/AN/ARDHLRedhill Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CLSD, EPIX, CYCN, and RDHL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026RDHLRedhill Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026CYCNCyclerion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026RDHLRedhill Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$3.33M0.64N/AN/A($7.68) per share-0.05CYCNCyclerion Therapeutics$2.07M6.84N/AN/A$2.31 per share1.42EPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/ARDHLRedhill Biopharma$290K16.57N/AN/A$0.83 per share1.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$34.35M-$5.19N/AN/AN/A-665.19%N/A-124.15%N/ACYCNCyclerion Therapeutics-$3.53M-$1.36N/AN/AN/A-170.11%-62.10%-55.14%8/4/2026 (Estimated)EPIXESSA Pharma-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/ARDHLRedhill Biopharma-$430K$1,046.750.00N/AN/AN/AN/AN/A8/20/2026 (Estimated)Latest CLSD, EPIX, CYCN, and RDHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CYCNCyclerion Therapeutics-$17.20-$0.76+$16.44-$0.76$0.88 millionN/A3/30/2026Q4 2025CYCNCyclerion Therapeutics-$0.38-$0.19+$0.19-$0.19$0.10 million$1.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AEPIXESSA Pharma$1.69839.96%N/AN/A N/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ALatest CLSD, EPIX, CYCN, and RDHL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100EPIXESSA Pharma--$1.698/25/20258/19/20258/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A3.873.87CYCNCyclerion TherapeuticsN/A1.801.80EPIXESSA PharmaN/A69.0669.06RDHLRedhill BiopharmaN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%CYCNCyclerion Therapeutics75.62%EPIXESSA Pharma75.12%RDHLRedhill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical6.70%CYCNCyclerion Therapeutics34.30%EPIXESSA Pharma15.50%RDHLRedhill Biopharma6.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical305.23 million4.89 millionOptionableCYCNCyclerion Therapeutics304.33 million2.85 millionNo DataEPIXESSA Pharma5047.31 million39.98 millionOptionableRDHLRedhill Biopharma2105.19 million4.84 millionNo DataCLSD, EPIX, CYCN, and RDHL HeadlinesRecent News About These CompaniesRedHill Biopharma Announces Closing of Up To $19.4 Million Private PlacementJune 22 at 4:10 PM | prnewswire.comRedHill Biopharma announces up to $19.4M private placementJune 18, 2026 | msn.comRedHill Biopharma Announces Up To $19.4 Million Private PlacementJune 18, 2026 | prnewswire.comRedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola OutbreakJune 13, 2026 | theglobeandmail.comRedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug DesignationJune 9, 2026 | finanznachrichten.deRedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug DesignationJune 9, 2026 | prnewswire.comRedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against KukboJune 8, 2026 | prnewswire.comRedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense PlatformsJune 2, 2026 | prnewswire.comBessor Announces Entering Option for the Redhill PropertyMay 26, 2026 | globenewswire.comRedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's DiseaseApril 30, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsApril 27, 2026 | finanznachrichten.deRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsApril 27, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical ...April 23, 2026 | finanznachrichten.deRedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026April 22, 2026 | prnewswire.comJoint U.S. Commercialization of RedHill's Talicia® CommencesFebruary 25, 2026 | prnewswire.comRedhill Biopharma stock soars on GLP-1 side effect treatment progressJanuary 5, 2026 | investing.comRedHill Biopharma shares jump on progress toward treating GLP-1 side effectsJanuary 5, 2026 | msn.comRedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side EffectsJanuary 5, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsDecember 15, 2025 | finanznachrichten.deRedHill Biopharma announces in vivo results on opaganib, venetoclaxDecember 15, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLSD, EPIX, CYCN, and RDHL Company DescriptionsClearside Biomedical NASDAQ:CLSDClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Cyclerion Therapeutics NASDAQ:CYCN$3.27 +0.05 (+1.55%) As of 06/23/2026 04:00 PM EasternCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.ESSA Pharma NASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Redhill Biopharma NASDAQ:RDHL$0.93 +0.09 (+10.24%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$0.94 +0.01 (+0.97%) As of 06/23/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
